{
    "clinical_study": {
        "@rank": "8386", 
        "acronym": "ViZIR", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D", 
                "arm_group_type": "Experimental", 
                "description": "Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "No Intervention", 
                "description": "Pegylated Interferon Alpha 2b + Ribavirin"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to show the superiority of a 4 weeks lead-in phase of Vitamin D\n      followed by a 48 weeks combination of Vitamin D with PEG-IFN plus RBV in comparison with\n      standard PEG-IFN + RBV in untreated Egyptian patients with chronic hepatitis C, on the\n      sustained virological response (SVR) at 3 months after end of treatment (week 60)."
        }, 
        "brief_title": "Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C", 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "- Method: Phase III, randomized, open-label superiority clinical trial, among Egyptian\n      patients with chronic hepatitis C.\n\n      - Treatment strategy: Vitamin D Arm: Vitamin D over a 4 weeks lead-in phase followed by\n      Vitamin D in combination with PEG-INF plus RBV during 48 weeks. Standard of Care Arm:\n      PEG-INF plus RBV during 48 weeks.\n\n      - Main outcome: Proportion of patients with Sustained Virological Response (SVR) as defined\n      by HCV RNA below the detection limit based on quantitative PCR 12 weeks after stopping\n      treatment.\n\n        -  Sample Size: 520 patients (260 per arm)\n\n        -  Enrollment period: 12 months\n\n        -  Patient's participation duration: 62 weeks (SOC Arm), 66 weeks (Vit-D Arm)\n\n        -  Statistical analysis:\n\n      The superiority of the vitamin D arm will be tested against the standard PEG IFN + RBV\n      combination. 260 patients in each arm will give 80% power to document a 12% difference in\n      the SVR rates between the experimental (Vitamin D) and the control (standard treatment)\n      arms..\n\n      A futility analysis is planned for this study, in order to be able to interrupt the trial\n      prematurely in case preliminary results show a lack of efficacy of vitamin D.\n\n      This analysis will be performed on half of the patients, thus 260 patients (130 patients per\n      arm), on a week 12/14 week criterion (HCV RNA viral load at W12/W14)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Common with National Program for Viral Hepatitis\n\n          -  Age: 18 years to 60 years\n\n          -  Positive HCV antibodies using a third generation test\n\n          -  Detectable HCV RNA by PCR\n\n          -  Liver biopsy showing chronic hepatitis with either a METAVIR score F1 with elevated\n             liver enzymes or scores F2/F3\n\n          -  Na\u00efve to treatment with PEG-IFN and RBV\n\n          -  HBs antigen negative\n\n          -  Prothrombin time \u226560 %, normal bilirubin, alpha-foeto protein < 3*normal range of the\n             laboratory, anti-nuclear antibodies<1/160 Effective contraception during the\n             treatment period; no breast-feeding\n\n        Specific to the trial\n\n          -  Prior approval from the Ministry of Health to be treated as part of the National\n             Program with allocation to Peg-IFN \u03b12b  treatment\n\n          -  Living <100 km from Cairo and able to come to the centre every week for the treatment\n\n          -  Signed informed consent and willingness to participate in the trial\n\n          -  Na\u00efve to treatment with vitamin D (received vitamin D less than 30 consecutive days\n             in the 3 months preceding inclusion)\n\n          -  Biopsy slide validated by NHTMRI pathologist\n\n        Exclusion Criteria:\n\n        Common with National program for Viral Hepatitis\n\n          -  Serious co-morbid conditions such as severe hypertension, heart failure, significant\n             coronary heart disease, poorly controlled diabetes (HbA1C>8%) , chronic obstructive\n             pulmonary disease\n\n          -  Major uncontrolled depressive illness\n\n          -  Solid transplant organ (renal, heart, or lung)\n\n          -  Untreated thyroid disease\n\n          -  History of previous anti-HCV therapy\n\n          -  Body mass index (BMI) greater than 30 kg/m\u00b2\n\n          -  Known human immunodeficiency virus (HIV) coinfection: although HIV testing will not\n             be proposed or done, patients with known HIV coinfection will not be included in the\n             trial\n\n          -  Anti-HCV therapy contraindications:\n\n          -  hypersensitivity to one of the two drugs (PEG-IFN, RBV)\n\n          -  pregnancy or unwilling to comply with adequate contraception\n\n          -  breast-feeding\n\n          -  neutropenia (<1500/mm3)\n\n          -  anaemia (<11g/dL for women ; <12g/dL for men)\n\n          -  thrombocytopenia (<100,000/mm3)\n\n          -  elevated creatinin (>1.5mg/dL)\n\n          -  concomitant liver disease other than hepatitis C (immuno-active chronic hepatitis B,\n             autoimmune hepatitis, alcoholic liver disease, hemochromatosis, alpha-1 antitrypsin\n             deficiency, Wilson disease)\n\n          -  liver biopsy showing severe steatosis (>66%) and steatohepatitis; decompensated\n             cirrhosis (Child Pugh>A); hepatocellular carcinoma, METAVIR score F4.\n\n          -  TSH>5 mU/L\n\n        Specific to the trial\n\n          -  Patients allocated to Peg-IFN alpha 2a treatment\n\n          -  Hypersensitivity to vitamin D\n\n          -  Vitamin D contraindications:\n\n          -  hypercalcaemia (fasting calcaemia >105 mg/L or 2.62 mmol/L)\n\n          -  ratio calciuria / creatininuria (fasting ratio >1 mmol Ca/mmol creatinin)\n\n          -  hyperphosphatemia (>1.5 mmol/L)\n\n          -  calcium lithiasis\n\n          -  patients being treated with thiazide diuretics (risk of hypercalcaemia with vitamin D\n             treatment)\n\n          -  patients being treated with glucocortico\u00efds (decrease in vitamin D efficacy)\n\n          -  postmenopausal women treated by vitamin D and calcium for osteoporosis\n\n          -  Treatment by vitamin D more than 30 consecutive days in the 3 months preceding\n             inclusion in the trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "520", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099604", 
            "org_study_id": "ANRS 12226 ViZIR"
        }, 
        "intervention": {
            "arm_group_label": "Vitamin D", 
            "description": "Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks", 
            "intervention_name": "Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin", 
            "intervention_type": "Drug", 
            "other_name": [
                "Vidrop", 
                "PegIntron", 
                "Rebetol"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferon Alfa-2b", 
                "Interferons", 
                "Ribavirin", 
                "Peginterferon alfa-2b", 
                "Reaferon", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatitis C - Genotype 4", 
            "SVR (Sustained Virological Response)", 
            "Vitamin D", 
            "Treatment Na\u00efve"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "NHTMRI"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of the Combination Vitamin D (Vit D), With Pegylated Interferon Alpha-2b (PEG-IFN)/Ribavirin (RBV) in Egyptian Patients With Untreated Chronic Hepatitis C: A Phase III Randomized Open-label Clinical Trial", 
        "overall_contact": {
            "email": "arnaud.fontanet@pasteur.fr", 
            "last_name": "Arnaud Fontanet, MD, PhD", 
            "phone": "+33140613763"
        }, 
        "overall_contact_backup": {
            "email": "muriel.vray@pasteur.fr", 
            "last_name": "Muriel Vray", 
            "phone": "+33140613982"
        }, 
        "overall_official": [
            {
                "affiliation": "NHTMRI, Cairo, Egypt", 
                "last_name": "Gamal Esmat, MD, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Institut Pasteur, Paris, France", 
                "last_name": "Arnaud Fontanet, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Egypt: Institutional Review Board", 
                "Egypt: Ministry of Health and Population"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of patients with Sustained Virological Response (SVR) as defined by HCV RNA below the detection limit based on quantitative PCR 12 weeks after stopping treatment.", 
            "measure": "Proportion of patients with Sustained Virological Response (SVR).", 
            "safety_issue": "No", 
            "time_frame": "60 Weeks after peg-IFN/RBV initiation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "HCV RNA at 4 weeks post initiation of combination therapy (PEG IFN + RBV)", 
                "measure": "Rapid Virological Response (RVR)", 
                "safety_issue": "No", 
                "time_frame": "4 Weeks after peg-IFN/RBV initiation"
            }, 
            {
                "description": "HCV RNA at 12 weeks post initiation of combination therapy", 
                "measure": "Early Virological Response (EVR)", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks after peg-IFN/RBV initiation"
            }, 
            {
                "description": "HCV RNA at end of treatment (week 48)", 
                "measure": "End of Treatment Response (ETR)", 
                "safety_issue": "No", 
                "time_frame": "48 Weeks after peg-IFN/RBV initiation"
            }, 
            {
                "measure": "Normalization of ALT during treatment and 12 weeks after the end of treatment", 
                "safety_issue": "No", 
                "time_frame": "From 2 Weeks after peg-IFN/RBV initiation to End of Follow-up (Week 60)"
            }, 
            {
                "description": "incidence of SAE leading to dosage reduction or treatment cessation, percentage of patients treated by EPO and G-CSF", 
                "measure": "Incidence of serious adverse events (SAE) grade 3 and 4 (ANRS scale)", 
                "safety_issue": "Yes", 
                "time_frame": "From Lead-in phase (Week -4) to End of Follow-up (Week 60)"
            }, 
            {
                "measure": "Evolution of FibroScan values between pre-inclusion and week 60", 
                "safety_issue": "No", 
                "time_frame": "At Screening Visit 2 (S2) and at End of Follow-up (Week 60)"
            }
        ], 
        "source": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
        "sponsors": {
            "collaborator": {
                "agency": "Institut Pasteur", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}